Nightstar Therapeutics, a UK biotech developing gene therapies for rare retinal diseases, announced terms for its IPO on Friday.
The London, United Kingdom-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. Insiders intend to purchase $25 million worth of shares in the offering. At the midpoint of the proposed range, Nightstar Therapeutics would command a fully diluted market value of $436 million.
Nightstar Therapeutics was founded in 2013 and plans to list on the Nasdaq under the symbol NITE. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of September 25, 2017.
